mTOR inhibitors

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Mammalian target of rapamycin (mTOR) protein complex functions as an integration center for various intracellular signaling pathways involving proliferation, cell survival, and angiogenesis. These pathways are frequently abnormally regulated in cancer. Notably, Akt is an upstream molecule which is over-expressed and/or activated in several cancers. Therefore, mTOR inhibitors can be options for the treatment of cancers. At present, mTOR inhibitors are applied to treat patients with metastatic renal cell carcinoma (RCC). Temsirolimus is indicated as the first line therapy for RCC patients with poor prognosis, whereas everolimus as the second line for those refractory to sorafenib or sunitinib. Interstitial pneumonia is the most serious adverse event for both agents. Clinical trials are under way to explore indications for various cancers.

Original languageEnglish
Pages (from-to)1067-1071
Number of pages5
JournalNippon rinsho. Japanese journal of clinical medicine
Volume68
Issue number6
Publication statusPublished - 2010 Jun

Fingerprint

Sirolimus
Renal Cell Carcinoma
Neoplasms
TOR Serine-Threonine Kinases
Interstitial Lung Diseases
Cell Survival
Clinical Trials
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

mTOR inhibitors. / Oya, Mototsugu.

In: Nippon rinsho. Japanese journal of clinical medicine, Vol. 68, No. 6, 06.2010, p. 1067-1071.

Research output: Contribution to journalArticle

@article{c2d4425a7ad24455a6708052574feeb8,
title = "mTOR inhibitors",
abstract = "Mammalian target of rapamycin (mTOR) protein complex functions as an integration center for various intracellular signaling pathways involving proliferation, cell survival, and angiogenesis. These pathways are frequently abnormally regulated in cancer. Notably, Akt is an upstream molecule which is over-expressed and/or activated in several cancers. Therefore, mTOR inhibitors can be options for the treatment of cancers. At present, mTOR inhibitors are applied to treat patients with metastatic renal cell carcinoma (RCC). Temsirolimus is indicated as the first line therapy for RCC patients with poor prognosis, whereas everolimus as the second line for those refractory to sorafenib or sunitinib. Interstitial pneumonia is the most serious adverse event for both agents. Clinical trials are under way to explore indications for various cancers.",
author = "Mototsugu Oya",
year = "2010",
month = "6",
language = "English",
volume = "68",
pages = "1067--1071",
journal = "Nihon rinsho. Japanese journal of clinical medicine",
issn = "0047-1852",
publisher = "Nipponrinsho Co., Inc.",
number = "6",

}

TY - JOUR

T1 - mTOR inhibitors

AU - Oya, Mototsugu

PY - 2010/6

Y1 - 2010/6

N2 - Mammalian target of rapamycin (mTOR) protein complex functions as an integration center for various intracellular signaling pathways involving proliferation, cell survival, and angiogenesis. These pathways are frequently abnormally regulated in cancer. Notably, Akt is an upstream molecule which is over-expressed and/or activated in several cancers. Therefore, mTOR inhibitors can be options for the treatment of cancers. At present, mTOR inhibitors are applied to treat patients with metastatic renal cell carcinoma (RCC). Temsirolimus is indicated as the first line therapy for RCC patients with poor prognosis, whereas everolimus as the second line for those refractory to sorafenib or sunitinib. Interstitial pneumonia is the most serious adverse event for both agents. Clinical trials are under way to explore indications for various cancers.

AB - Mammalian target of rapamycin (mTOR) protein complex functions as an integration center for various intracellular signaling pathways involving proliferation, cell survival, and angiogenesis. These pathways are frequently abnormally regulated in cancer. Notably, Akt is an upstream molecule which is over-expressed and/or activated in several cancers. Therefore, mTOR inhibitors can be options for the treatment of cancers. At present, mTOR inhibitors are applied to treat patients with metastatic renal cell carcinoma (RCC). Temsirolimus is indicated as the first line therapy for RCC patients with poor prognosis, whereas everolimus as the second line for those refractory to sorafenib or sunitinib. Interstitial pneumonia is the most serious adverse event for both agents. Clinical trials are under way to explore indications for various cancers.

UR - http://www.scopus.com/inward/record.url?scp=77955867552&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77955867552&partnerID=8YFLogxK

M3 - Article

C2 - 20535957

AN - SCOPUS:77955867552

VL - 68

SP - 1067

EP - 1071

JO - Nihon rinsho. Japanese journal of clinical medicine

JF - Nihon rinsho. Japanese journal of clinical medicine

SN - 0047-1852

IS - 6

ER -